[{"orgOrder":0,"company":"Ziphius Vaccines","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"ZIP-1642","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ziphius Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ziphius Vaccines \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Ziphius Vaccines \/ Charles River Laboratories, Inc"}]

Find Clinical Drug Pipeline Developments & Deals by Ziphius Vaccines

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Ziphius Vaccines is developing a proprietary self-amplifying mRNA technology platform combined with innovative lipid formulations for delivery. saRNA or replicon RNA has the advantage of having self-replicating features.

                          Product Name : ZIP-1642

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 23, 2022

                          Lead Product(s) : ZIP-1642

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Charles River Laboratories, Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank